Reports Q3 revenue $117.085M, consensus $112.5M. “Our third quarter performance continues to build on the outstanding year we are having, with significant revenue growth, strong patient demand, pipeline advancement and operating profitability in the quarter. As we look ahead, we see robust and durable revenue growth, new opportunities for younger children to benefit from ORLADEYO, and data readouts from BCX17725 in Netherton syndrome and avoralstat in DME, all while moving closer to sustainable profitability,” said Jon Stonehouse, president and chief executive officer of BioCryst (BCRX).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCRX:
- BioCryst Pharmaceuticals (BCRX) Q3 Earnings Cheat Sheet
- BioCryst presents evidence on high adherence, persistence rates with ORLADEYO
- BioCryst to present real-world evidence on oral ORLADEYO
- Two Key Products Drive BioCryst (BCRX) to New Highs
- BioCryst reports inducement grants under Nasdaq listing rule
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%2C%20consensus%20(6c)%20%7C%20Nasdaq&_biz_n=1&rnd=839054&cdn_o=a&_biz_z=1743608725524)
%2C%20consensus%20(6c)%20%7C%20Nasdaq&rnd=391931&cdn_o=a&_biz_z=1743608725528)